A1C Almanac

Main Page

The Mini Polypill in Your Kitchen Drawer

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:

Keywords: Allium Sativum, Metformin, Organosulfur Compounds, S-Allylcysteine, Aged Garlic Extract, Insulin Resistance, Nutraceutical Adjunct, Metabolic Syndrome

Why Talk About Garlic as “The New Metformin?”

Metabolic syndrome, prediabetes, and type 2 diabetes have become highly prevalent conditions worldwide and now represent a default trajectory for a substantial proportion of the global population. These interrelated disorders are strongly associated with an increased risk of cardiovascular disease, non-alcoholic fatty liver disease, chronic kidney disease, and accelerated biological aging. In contemporary clinical practice, metformin remains the first-line pharmacologic agent for the management of type 2 diabetes due to its low cost, extensive safety and efficacy data, and favourable effects on glycemic control, body weight, and overall cardiometabolic risk. Despite these advantages, metformin use may be limited by gastrointestinal side effects, vitamin B12 deficiency, and contraindications in certain patient groups, underscoring the ongoing need for complementary and preventive strategies

In parallel with these epidemiologic and clinical challenges, there is growing interest from both patients and clinicians in “food as medicine” and metabolically intelligent nutrition. Individuals at risk for or living with metabolic disease increasingly seek non-pharmacologic options and frequently pose the question of whether a “natural version of metformin” exists. Although no food can substitute for pharmacotherapy in patients who clearly require glucose-lowering medication, emerging evidence suggests that specific dietary components can modulate key metabolic pathways that overlap with the mechanisms targeted by metformin. This has stimulated scientific and public interest in nutraceuticals and functional foods as adjuncts to standard care in metabolic disease and longevity-focused interventions.

Among these candidates, garlic (Allium sativum) is particularly notable because it is widely consumed, culturally acceptable, and rich in bioactive organosulfur compounds, including allicin and S-allylcysteine. Experimental and clinical studies indicate that garlic may exert beneficial effects on multiple cardiometabolic domains, including blood glucose regulation, lipid profile, blood pressure, inflammatory signalling, and oxidative stress. These pleiotropic actions align closely with the biological hallmarks targeted by metformin and position garlic as a compelling dietary component in the context of metabolic health. The present article examines whether it is scientifically justified to consider garlic as “the new metformin” or whether it is more appropriate to conceptualize garlic as a nutraceutical adjunct that complements, rather than replaces, metformin within an integrated strategy for prevention and management of metabolic 

Metformin in One Page: What Does it Actually Do?

Metformin is a biguanide antihyperglycemic agent that remains the recommended first-line pharmacotherapy for type 2 diabetes in most international guidelines, owing to its efficacy, safety profile, low cost, and potential cardiovascular and longevity benefits. Its principal glucose-lowering effect is mediated by suppression of hepatic gluconeogenesis, resulting in reduced hepatic glucose output and consequently lower fasting plasma glucose concentrations. At the cellular level, metformin inhibits mitochondrial respiratory-chain complex I, leading to an increased AMP:ATP ratio and subsequent activation of AMP-activated protein kinase (AMPK), a key energy sensor that orchestrates downstream metabolic adaptations. Through AMPK-dependent and AMPK-independent pathways, metformin enhances insulin sensitivity, promotes peripheral glucose uptake, and shifts cellular metabolism away from energy storage toward catabolic, energy-expending processes [1-4.

Beyond its effects on glycemia, metformin exerts modest but clinically relevant improvements in lipid metabolism, typically reducing triglycerides and low-density lipoprotein (LDL) cholesterol, while having a neutral to slightly beneficial effect on body weight. Importantly, metformin has been shown to attenuate chronic low-grade inflammation and oxidative stress, which are central to the pathophysiology of vascular damage, insulin resistance, and accelerated biological aging. These pleiotropic actions contribute to a more favourable cardiometabolic risk profile and may underlie observations from large cohort studies and post-trial follow-ups suggesting reduced macrovascular complications and possible mortality benefits in people treated with metformin compared with other glucose-lowering regimens. This constellation of metabolic, vascular, and potentially geroprotective effects has led to growing interest in metformin as a candidate “longevity drug,” including its evaluation in aging-focused research protocols such as the proposed TAME (Targeting Aging with Metformin) trial [2,5,6].

However, metformin is not without limitations. Gastrointestinal adverse effects, including nausea, abdominal discomfort, and diarrhea are common, particularly at treatment initiation or with rapid dose escalation, and may limit adherence in a subset of patients. Long-term use has been associated with vitamin B12 deficiency, necessitating periodic monitoring and supplementation in at-risk individuals. Metformin is contraindicated or requires dose adjustment in advanced renal impairment and certain hepatic or hypoxic conditions due to the rare but serious risk of lactic acidosis. In addition, many individuals in the “grey zone” of metabolic dysfunction, those with prediabetes, insulin resistance, or early metabolic syndrome prefer to prioritize lifestyle-based strategies and nutraceutical approaches before initiating pharmacotherapy. These clinical realities create a space for adjunctive, food-based interventions that target overlapping metabolic pathways. Within this context, garlic (Allium sativum), with its documented effects on glycemic control, lipid parameters, blood pressure, inflammation, and oxidative stress, has emerged as a particularly interesting candidate to be considered alongside metformin in comprehensive, prevention and longevity-oriented metabolic care [2,7]. 

Garlic’s Pharmacology: More Than Just Smell

Garlic (Allium sativum) exerts its biological effects through a complex mixture of bioactive constituents that are generated when cloves are chopped, crushed, or subjected to aging and fermentation processes. The most studied compounds are organosulfur molecules, including allicin, S-allylcysteine (SAC), S-allylmercaptocysteine (SAMC), and various allyl sulfides, which are derived primarily from the precursor alliin and γ-glutamyl-cysteine peptides. These organosulfur compounds, together with phenolic compounds, flavonoids, saponins, and polysaccharides, are considered responsible for the majority of garlic’s pharmacological properties, including its cardiometabolic, anti-inflammatory, antioxidant, and immunomodulatory actions. Processing conditions (e.g., raw, aged, black garlic) markedly influence the profile, stability, and bioavailability of these constituents, which partly explains the heterogeneity of responses observed across clinical trials [8-11].

With respect to glucose homeostasis, experimental and clinical data indicate that garlic can modulate several key nodes of insulin signalling and glycemic control. In animal models of insulin resistance and type 2 diabetes, oral administration of raw garlic homogenate improves insulin sensitivity, enhances peripheral glucose uptake, and normalizes elevations in fasting glucose, insulin, and triglycerides, while attenuating oxidative stress in hepatic tissue. Mechanistic studies suggest that organosulfur compounds may augment insulin receptor signalling and glucose transporter activity, reduce hepatic gluconeogenesis, and, in some settings, modestly stimulate insulin secretion from pancreatic β-cells. In human trials, these mechanisms translate into reductions in fasting plasma glucose, post-prandial glucose, and, over weeks to months of supplementation, significant decreases in HbA1c compared with placebo or usual care, particularly when garlic is used as an adjunct in patients with type 2 diabetes or metabolic syndrome [5,13,14].

Garlic also exerts clinically meaningful effects on lipid metabolism. Meta-analyses and randomized controlled trials have consistently reported that garlic supplementation can lower total cholesterol and low-density lipoprotein (LDL) cholesterol, reduce triglyceride concentrations, and, in some populations, modestly increase high-density lipoprotein (HDL) cholesterol. These lipid-modifying effects appear to be more pronounced in individuals with elevated baseline lipid levels and when standardized preparations, such as aged garlic extract or defined organosulfur formulations, are employed. Proposed mechanisms include inhibition of hepatic enzymes involved in cholesterol and fatty-acid synthesis, enhanced biliary excretion of cholesterol, and improved resistance of LDL particles to oxidative modification [5,10,13,15].

In the vascular domain, garlic has been shown to favourably influence blood pressure and endothelial function. Organosulfur compounds exhibit angiotensin-converting enzyme (ACE) inhibitory activity, increase nitric oxide (NO) bioavailability, and may modulate endogenous hydrogen sulfide (H₂S) signalling, leading to vasodilation and improved arterial compliance. Clinical trials in individuals with mild to moderate hypertension or metabolic syndrome demonstrate that garlic supplementation can reduce systolic and diastolic blood pressure, in some cases with magnitudes comparable to those seen with low-dose antihypertensive therapy. Improvements in indices of arterial stiffness and endothelial function have also been reported, further supporting a direct vascular protective effect [5,12,13,16].
Garlic’s anti-inflammatory and antioxidant properties are central to its relevance for metabolic disease and longevity. Both raw and processed (e.g., black) garlic preparations reduce markers of lipid peroxidation such as thiobarbituric acid-reactive substances (TBARS) and enhance endogenous antioxidant defenses by increasing levels or activity of glutathione, superoxide dismutase, catalase, and related enzymes in experimental models. In parallel, garlic and its organosulfur constituents downregulate pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and modulate signalling pathways implicated in chronic low-grade inflammation. Given that oxidative stress and subclinical inflammation are key drivers of insulin resistance, endothelial dysfunction, and vascular aging, these pleiotropic actions provide a mechanistic bridge between garlic intake and improved metabolic and cardiovascular outcomes [10- 16].

Finally, a growing body of evidence supports organ-protective effects of garlic in the context of metabolic and toxic insults. In rodent models of fructose-induced metabolic syndrome, dietary garlic attenuates hepatic oxidative stress and restores redox balance, while improving insulin sensitivity and normalizing dyslipidemia. Black garlic and related preparations have been shown to protect hepatic and renal cells by reducing advanced glycation end-product formation, lowering lipid peroxidation, and upregulating antioxidant enzyme activity, thereby mitigating structural and functional damage in liver and kidney tissue. Cardioprotective effects have also been described in experimental ischemia–reperfusion models, where garlic reduces infarct size and oxidative injury, particularly when combined with other metabolic drugs such as metformin. Collectively, these data support the view that garlic is not a single-target agent but rather a multi-component, multi-pathway intervention that functions as a “mini-polypill,” simultaneously addressing dysglycemia, dyslipidemia, hypertension, inflammation, oxidative stress, and organ damage in the setting of metabolic syndrome and related disorders [1,2,5,12-16].

Head-to-Head: Metformin vs Garlic (and When They Team Up)

From a glycemic perspective, several randomized and quasi-experimental trials have evaluated garlic in individuals with type 2 diabetes or prediabetes, most often as an adjunct to standard pharmacologic therapy. In patients already treated with metformin, the addition of garlic has been associated with further reductions in fasting blood glucose and post-prandial glucose compared with metformin alone, although sample sizes have generally been small and follow-up durations limited. A single-blind, placebo-controlled study directly comparing metformin with garlic preparations in type 2 diabetes reported that 10 g/day of garlic given for two months reduced fasting blood glucose by approximately 25.5 mg/dL, approaching the 28.4 mg/dL reduction observed with 250 mg metformin three times daily, both changes being highly statistically significant relative to baseline. Systematic reviews and meta-analyses of randomized controlled trials support these findings, showing that garlic supplementation significantly lowers fasting blood sugar and HbA1c compared with placebo or usual care, with pooled weighted mean differences in fasting glucose in the range of 7–12 mg/dL and HbA1c reductions of around 0.5–0.7 percentage points, particularly in interventions lasting at least 8–12 weeks. Taken together, these data suggest that garlic behaves as a mild antidiabetic agent with clinically relevant but generally smaller and more variable glycemic effects than standard-dose metformin, while the combination of garlic with metformin tends to provide superior glycemic control compared with metformin alone [6,17- 19].

In individuals with metabolic syndrome, overweight, or dyslipidemia, garlic also demonstrates a broader “metabolic fingerprint” that resembles the extended benefits of metformin beyond glucose lowering. Meta-analytic evidence indicates that garlic supplementation significantly reduces triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterol, with some trials reporting modest increases in high-density lipoprotein (HDL) cholesterol, particularly in participants with elevated baseline lipid levels and with longer intervention durations. Parallel improvements in systolic and diastolic blood pressure have been observed, with pooled standardized mean differences indicating clinically meaningful declines in diastolic blood pressure and smaller but directionally favourable changes in systolic values. Several trials in patients with metabolic syndrome report additional benefits on markers of insulin resistance, waist circumference, and indices of non-alcoholic fatty liver disease, reinforcing the view that garlic influences multiple cardiometabolic domains simultaneously. Although metformin remains more potent with respect to glucose and insulin sensitivity, both interventions appear to converge on improvements in lipids, blood pressure, and inflammatory/oxidative stress markers, supporting the notion that garlic partly recapitulates metformin’s multi-system metabolic effects [5,13,14,19].

Preclinical work further elucidates the potential synergy between garlic and metformin. In diabetic rodent models, co-administration of garlic homogenate and metformin has been shown to confer greater protection against oxidative damage and metabolic derangements than either agent alone, including more pronounced normalization of antioxidant enzyme activities (such as superoxide dismutase and catalase) and reductions in thiobarbituric acid-reactive substances. Experimental studies in models of ischemia–reperfusion injury demonstrate that combined garlic–metformin therapy enhances cardioprotection, with improved recovery of hemodynamic parameters, reduced infarct size, and better preservation of myocardial histoarchitecture compared with monotherapy. Similar nephroprotective and hepatoprotective trends have been described in settings of drug-induced or metabolic kidney and liver injury, where the combination appears to augment antioxidant defenses and mitigate structural damage. Early clinical data, including subgroup analyses from meta-analyses, suggest that garlic used alongside oral hypoglycemic agents yields greater improvements in LDL cholesterol and other lipid parameters than garlic alone, although the number of well-designed trials specifically powered to test garlic–metformin interactions remains limited and heterogeneous. Conceptually, these findings support a model in which metformin functions as a central insulin-sensitizing and gluconeogenesis-suppressing drug, while garlic acts as a pleiotropic biochemical adjunct that strengthens improvements in lipids, blood pressure, oxidative stress, inflammation, and organ integrity, together providing a more comprehensive cardiometabolic and potentially geroprotective effect than either intervention alone [1,2,5,13,16,19].

Safety, Dosing, and The Real-World Garlic Problem

From a safety perspective, garlic is generally well tolerated at both culinary and supplemental doses, with most reported adverse effects being mild and reversible. The most common reactions in clinical trials and observational reports include gastrointestinal discomfort (such as bloating, abdominal pain, dyspepsia, and loose stools) and characteristic garlic breath or body odor. Meta-analyses of long-term garlic supplementation indicate that the overall incidence of adverse events is only slightly higher than in control groups, and that these events are predominantly minor digestive complaints and halitosis rather than serious toxicity. Nevertheless, garlic possesses antiplatelet properties, attributed particularly to organosulfur derivatives such as ajoene which can potentiate the effects of anticoagulant and antiplatelet medications and, in susceptible individuals or at high doses, may increase bleeding risk. Case reports and pharmacovigilance data describe episodes of excessive anticoagulation or bleeding in patients combining garlic with warfarin and other blood thinners, and controlled studies have demonstrated measurable effects of garlic on platelet aggregation and coagulation parameters at higher supplemental doses. In addition, allergic reactions, including contact dermatitis, urticaria, angioedema, and rare anaphylactic events, have been documented. Overall, most randomized trials in hypertension, dyslipidemia, and type 2 diabetes report good tolerability when garlic or aged garlic extract is used in typical study doses alongside standard therapies, including metformin, but robust long-term safety data in older, multimorbid patients on complex polypharmacy remain limited [5,14,20-26].

Dosing and formulation represent major challenges for the clinical translation of garlic as a metabolic intervention. Trials have employed a wide variety of preparations, including raw crushed garlic, oils, powders, aged garlic extract, and encapsulated standardized products, each with distinct profiles of organosulfur compounds and differing stability and bioavailability. The content and pharmacokinetics of key bioactives such as allicin and S-allylcysteine can vary by more than an order of magnitude between products, depending on cultivar, processing (e.g., aging, fermentation, dehydration), storage conditions, and formulation. Aged garlic extract, which is standardized to S-allylcysteine content, has been the most extensively studied in controlled hypertension and cardiovascular risk trials; these studies suggest that daily doses around 1.2 g of aged extract (typically providing approximately 1.2 mg S-allylcysteine) can significantly reduce peripheral and central blood pressure and favorably influence arterial stiffness and inflammatory markers, with high tolerability and no excess bleeding even in patients on background antihypertensive or antiplatelet therapy. Recent meta-analytic work indicates that an S-allylcysteine intake in the approximate range of 0.5–1.5 mg per day may be optimal for balancing efficacy and safety in cardiovascular applications [8,10,21,23,27].

Given this heterogeneity, it is not possible to define a simple, evidence-based equivalence such as “X cloves of garlic equals Y milligrams of metformin” in terms of metabolic impact. The relationship between dose, preparation, and clinical effect is non-linear, and the lack of universal standardization of garlic supplements further complicates extrapolation across products. For lifestyle-first individuals with prediabetes, metabolic syndrome, or early dyslipidemia, a pragmatic, evidence-informed approach is to encourage regular culinary use of garlic, preferably crushed or chopped and allowed to stand briefly before cooking to enhance allicin formation within a whole-food, high-fibre dietary pattern, and to consider a standardized aged garlic extract at doses similar to those used in clinical trials when specifically targeting blood pressure or lipid modulation. Such use should be integrated with foundational lifestyle interventions, including resistance and aerobic training, time-restricted or otherwise structured eating patterns, adequate sleep, and stress regulation, and accompanied by monitoring of blood glucose, blood pressure, and lipid profiles. For patients already receiving metformin or other glucose-lowering agents, garlic is best employed as an adjunctive nutraceutical or dietary component rather than a substitute, with particular attention to potential drug–herb interactions in those on anticoagulant or antiplatelet therapy and in frail, multimorbid populations [5,10,13,14,20,23,28,29].

So, is Garlic “The New Metformin?”

Whether garlic can be regarded as “the new metformin” remains an open but carefully bounded question. Current evidence indicates that garlic exerts metformin-like effects across several metabolic domains, including improvements in glycemic control, insulin resistance, lipid profile, blood pressure, and markers of inflammation and oxidative stress. Experimental models further demonstrate that garlic provides cardio-, nephro-, and hepatoprotective effects under diabetic and ischemia–reperfusion conditions, and that co-administration with metformin can augment antioxidant defences and structural preservation of target organs. From a public-health perspective, garlic is also attractive because it is inexpensive, widely available, and deeply embedded in diverse culinary traditions, factors that may favour long-term adherence relative to additional pharmacologic pills [1,5,13,21].

Conversely, there are important and non-trivial distinctions between garlic and metformin. Metformin’s glucose-lowering efficacy is stronger and more consistent, with typical HbA1c reductions of approximately 1–1.3% in monotherapy and large-scale data supporting its role in both treatment and prevention of type 2 diabetes, as exemplified by the Diabetes Prevention Program and subsequent analyses. Garlic’s metabolic effects, while statistically and clinically meaningful in many trials, are generally more modest and heterogeneous, influenced by preparation, dose, treatment duration, and baseline risk profile, as reflected in meta-analyses where pooled reductions in fasting glucose and blood pressure are significant but smaller in magnitude than those seen with standard antihyperglycemic or antihypertensive medications. Moreover, robust, long-term, head-to-head comparisons of standardized garlic preparations versus metformin on hard outcomes, such as incident diabetes, major adverse cardiovascular events, or mortality are lacking, in contrast to the decades of clinical experience and outcomes data available for metformin [17,21,31].

In light of these considerations, the most defensible and clinically responsible framing is to position garlic not as a one-to-one replacement for metformin in individuals who meet clear indications for pharmacotherapy, but rather as a promising, pleiotropic adjunct within a broader food-as-medicine and lifestyle-based strategy. For patients with established type 2 diabetes, garlic, preferably in standardized, evidence-based formulations may be integrated alongside metformin and other guideline-directed therapies to enhance glycemic control, lipid and blood pressure management, and inflammatory/oxidative profiles, while recognizing the need for individualized monitoring and attention to potential drug–herb interactions. In earlier stages of metabolic dysfunction, such as prediabetes, metabolic syndrome, or insulin resistance in high-risk but non-diabetic individuals, garlic-rich dietary patterns and adjunctive supplementation may play a meaningful role in delaying progression and reducing the intensity or timing of pharmacologic intervention, especially when combined with structured exercise, weight management, and other lifestyle modifications. Thus, rather than supplanting metformin as a “new” pharmacologic standard, garlic is better conceptualized as a metabolically active functional food and nutraceutical tool that complements the central role of metformin in comprehensive, longevity-oriented metabolic care [5,6,13,14,30-34].

Conclusion

From a clinical and digital health perspective, garlic can be incorporated into preventive and longevity-oriented protocols as a structured, evidence-informed adjunct rather than as a stand-alone pharmacologic replacement. It is best positioned as a metabolically active functional food or nutraceutical component that complements established therapies, including metformin, within comprehensive cardiometabolic risk-reduction strategies. Framing garlic in this way allows clinicians to avoid overstating its effects while still leveraging its pleiotropic benefits on glycemic control, lipid metabolism, blood pressure, and inflammatory and oxidative pathways.

For patient communication and engagement, the concept of garlic as a “nutritional metformin” can serve as a useful metaphor to facilitate understanding and motivate behaviour change, provided that the limitations of this analogy are clearly articulated. Clinicians should emphasize that, unlike metformin, garlic’s effects are generally more modest and variable, and are most appropriately applied as part of a broader lifestyle prescription rather than as a substitute for indicated pharmacotherapy. Integrating garlic into protocols alongside resistance and aerobic training, sleep optimization, stress management, and fibre-rich, minimally processed dietary patterns can help construct a coherent, multi-targeted metabolic health program.

Within health-technology and AI-driven care models, garlic-containing dietary or supplementation strategies can be incorporated into decision-support algorithms and personalized intervention pathways. Continuous glucose monitoring, lipid panels, blood pressure trends, body composition, and composite “metabolic age” indices can be used to identify individuals who appear to respond favourably to garlic-based interventions, enabling iterative refinement of recommendations over time. In an era where metabolic dysfunction is increasingly prevalent, integrating rigorously evaluated, food-based strategies such as garlic into digital and clinical care pathways represents an expansion, rather than a rejection, of pharmacologic options. Metformin is likely to remain the gold-standard pharmacologic agent for many patients with type 2 diabetes, but garlic has the potential to become one of the core dietary components in a modern, longevity-focused approach to metabolic health

Reference

  1. Azar Baradaran, Mahmoud Rafieian-Kopaei. Histopathological study of the combination of metformin and garlic juice for the attenuation of gentamicin renal toxicity in rats. PubMed. 2013 Jan 1;
  2. Basheeruddin M, S. Lokaraja, Alamri AS, Alsanie WF, Majid Alhomrani, Abdulrahman Hadi Almutiri, et al. Potential Interaction of Fresh Garlic with Metformin during Ischemia-Reperfusion Induced Cardiac Injury in Diabetic Rats. Evidence-based Complementary and Alternative Medicine. 2021 Sep 4;2021:1–12.
  3. Becky. Study Finds 4 Ways Garlic Benefits Diabetics – Natural Health Research [Internet]. Natural Health Research – Where Science Supports Wellness. 2016 [cited 2026 Apr 8]. Available from: https://naturalhealthresearch.org/study-finds-4-ways-garlic-benefits-diabetics/
  4. Basheeruddin M, S. Lokaraja, Alamri AS, Alsanie WF, Majid Alhomrani, Abdulrahman Hadi Almutiri, et al. Potential Interaction of Fresh Garlic with Metformin during Ischemia-Reperfusion Induced Cardiac Injury in Diabetic Rats. Evidence-based Complementary and Alternative Medicine. 2021 Sep 4;2021:1–12.
  5. Fu Z, Lv J, Gao X, Zheng H, Shi S, Xu X, et al. Effects of garlic supplementation on components of metabolic syndrome: a systematic review, meta-analysis, and meta-regression of randomized controlled trials. BMC complementary medicine and therapies [Internet]. 2023 Jul 22;23(1):260. Available from: https://pubmed.ncbi.nlm.nih.gov/37481521/
  6. Saleem A, Memon A, Niaz K, Shahina, Khan M, Qudoos A, et al. Metformin and Garlic Preparations for Hyperglycemia. International Archives of BioMedical and Clinical Research [Internet]. 2017 [cited 2026 Apr 8];77–80. Available from: https://iabcr.org/index.php/iabcr/article/view/654
  7. Safiriyu AA, Semuyaba I, Lawal SK, Buhari MO, Tiyo EA, Kalange M, et al. Comparative Study of the Effects of Metformin and Garlic Extract on Hippocampal Na+/K+ ATPase, Ca2+ ATPase and Glutamine Synthetase Activities in Type II Diabetic Wistar Rat. Journal of Biomedical Science and Engineering [Internet]. 2018 [cited 2026 Apr 8];11(09):254–62. Available from: https://www.scirp.org/journal/paperinformation?paperid=87599
  8. Omar SH, Al-Wabel NA. Organosulfur compounds and possible mechanism of garlic in cancer. Saudi Pharmaceutical Journal [Internet]. 2010 Jan;18(1):51–8. Available from: https://www.sciencedirect.com/science/article/pii/S1319016409000528
  9. Bazaraliyeva A, Moldashov D, Turgumbayeva A, Kartbayeva E, Kalykova A, Sarsenova L, et al. Chemical and biological properties of bio-active compounds from garlic (Allium sativum). Pharmacia. 2022 Oct 31;69(4):955–64.
  10. Melguizo-Rodríguez L, García-Recio E, Ruiz C, Luna-Bertos ED, Illescas-Montes R, J. Costela-Ruiz V. Biological properties and therapeutic applications of garlic and its components. Food & Function [Internet]. 2022;13(5):2415–26. Available from: https://pubs.rsc.org/en/content/articlehtml/2022/fo/d1fo03180e
  11. Higdon J, Drake VJ, editors. Organosulfur Compounds from Garlic. An Evidence-based Approach to Phytochemicals and Other Dietary Factors. 2013;
  12. Padiya R, Khatua TN, Bagul PK, Kuncha M, Banerjee SK. Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed rats. Nutrition & Metabolism [Internet]. 2011 [cited 2019 Nov 9];8(1):53. Available from: https://nutritionandmetabolism.biomedcentral.com/articles/10.1186/1743-7075-8-53
  13. Shruti Varade, Nadella M, Amol Hirake, Suraj bhausaheb Mungase, Ramu Adela. Effect of garlic on the components of metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Journal of ethnopharmacology. 2024 Jan 1;318:116960–0.
  14. Pérez-Rubio KG, Méndez-del Villar M, Cortez-Navarrete M. The Role of Garlic in Metabolic Diseases: A Review. Journal of Medicinal Food. 2022 Jul 1;25(7):683–94.
  15. Kamdar D. From heart health to drug interactions: garlic’s effect on the body. Edwards K, editor. 2025 Nov 12; Available from: https://theconversation.com/from-heart-health-to-drug-interactions-garlics-effect-on-the-body-266646
  16. None Saryono, None Sarmoko, Nani D, Atikah Proverawati, Agis Taufik. Black solo garlic protects hepatic and renal cell function in streptozotocin-induced rats. Frontiers in Nutrition [Internet]. 2022 Nov 29 [cited 2025 Feb 16];9. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9745152/
  17. Wang J, Zhang X, Lan H, Wang W. Effect of garlic supplement in the management of type 2 diabetes mellitus (T2DM): a meta-analysis of randomized controlled trials. Food & Nutrition Research. 2017 Jan;61(1):1377571.
  18. Hou LQ, Liu YH, Zhang YY. Garlic intake lowers fasting blood glucose: meta-analysis of randomized controlled trials. Asia Pac J Clin Nutr [Internet]. 2015;24(4):575–82. Available from: https://pdfs.semanticscholar.org/1039/2ae1529b02395b47c3f9b769cdaf0fbc3361.pdf
  19. Ebrahimzadeh A, Safargar M, Rajabzadeh-Dehkordi M, Nematolahi F, Samadani M, Saeid L, et al. The Therapeutic Effect of Garlic Supplements on the Metabolic Profile of Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrition and Metabolic Insights [Internet]. 2026 Feb;19. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12901877/
  20. Lawn A, Sains P. Comment on: Not just a vampire repellent: the adverse effects of garlic supplements in surgery. Annals of The Royal College of Surgeons of England [Internet]. 2012 Sep 1;94(6):451–1. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954349/
  21. Lei Y, Tu Q, Mao X, Huang N, Jiang Q. Meta-analysis on the safety and efficacy of long-term garlic consumption as an adjunctive treatment for hypertension. Frontiers in Nutrition. 2025 Nov 28;12.
  22. H Fakhar, A Hashemi Tayer. Effect of the Garlic Pill in comparison with Plavix on Platelet Aggregation and Bleeding Time. Iranian Journal of Pediatric Hematology and Oncology [Internet]. 2012 Sep 22;2(4):146. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3915434/
  23. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial. Integrated Blood Pressure Control. 2016 Jan;9:9.
  24. F B, R C, Aa I. Garlic (Allium Sativum L.): Adverse Effects and Drug Interactions in Humans [Internet]. Molecular nutrition & food research. 2007. Available from: https://pubmed.ncbi.nlm.nih.gov/17918162/
  25. Pereverzev AP, Ostroumova OD. Potential drug interactions with garlic. Medical alphabet [Internet]. 2021 Oct 19 [cited 2025 Feb 3];1(29):47–51. Available from: https://www.med-alphabet.com/jour/article/view/2260
  26. Mojtaba Shafiekhani, Faridi P, Javad Kojuri, Namazi S. Comparison of antiplatelet activity of garlic tablets with cardio-protective dose of aspirin in healthy volunteers: a randomized clinical trial. Avicenna Journal of Phytomedicine [Internet]. 2016 Sep;6(5):550. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5052418/
  27. Hossain MS, Md. Shahiduzzaman, Rahim MA, Paul M, Sarkar R, Farjana Showline Chaity, et al. Bioactive properties and organosulfur compounds profiling of newly developed garlic varieties of Bangladesh. Food Chemistry X [Internet]. 2023 Jan 13 [cited 2025 Feb 23];17:100577–7. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9944507/?utm_source=chatgpt.com
  28. F B, R C, Aa I. Garlic (Allium Sativum L.): Adverse Effects and Drug Interactions in Humans [Internet]. Molecular nutrition & food research. 2007. Available from: https://pubmed.ncbi.nlm.nih.gov/17918162/
  29. Evaluations P and B, Kansara M. Possible interactions between garlic and conventional drugs: a review. wwwacademiaedu [Internet]. Available from: https://www.academia.edu/32901058/Possible_interactions_between_garlic_and_conventional_drugs_a_review
  30. Aroda VR, Ratner RE. Metformin and type 2 diabetes prevention. Diabetes Spectrum [Internet]. 2018;31(4):336–42. Available from: https://spectrum.diabetesjournals.org/content/31/4/336
  31. Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes? Therapeutic Advances in Endocrinology and Metabolism [Internet]. 2021 Jan 13;12(12):204201882098022. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7809522/
  32. Rafah Manafikhi, IJASR Journal. Effects of Garlic Supplementation on Fasting Blood Sugar, HbA1c and Lipid Profile in Type 2 Diabetics Receiving Metformin and Glyburide [Internet]. Academia.edu. 2016 [cited 2026 Apr 8]. Available from: https://www.academia.edu/22253332/Effects_of_Garlic_Supplementation_on_Fasting_Blood_Sugar_HbA1c_and_Lipid_Profile_in_Type_2_Diabetics_Receiving_Metformin_and_Glyburide
  33. Juliana, Yang A, Chu N, Chow E. Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin. Diabetes, obesity & metabolism/Diabetes, obesity and metabolism. 2024 Jul 11;
  34. Kret DI, Szlachta WK, Anczyk A, Handzel K, Zaborowski G, Wysoczański J, et al. The effect of garlic on carbohydrate metabolism and glycaemic control: a review of the literature. Lekarz Wojskowy [Internet]. 2026 Mar 31 [cited 2026 Apr 8];104(1):50–3. Available from: https://lekarzwojskowy.wim.mil.pl/pdf-213374-138056?filename=The-effect-of-garlic-on-c.pdf

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading